An Overview of Mucosa-Associated Protozoa: Challenges in Chemotherapy and Future Perspectives

Parasitic infections caused by protozoans that infect the mucosal surfaces are widely neglected worldwide. Collectively, Entamoeba histolytica, Giardia lamblia, Cryptosporidium spp. and Trichomonas vaginalis infect more than a billion people in the world, being a public health problem mainly in deve...

Full description

Bibliographic Details
Main Authors: Helena Lucia Carneiro Santos, Karina M. Rebello
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Cellular and Infection Microbiology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcimb.2022.860442/full
_version_ 1818127118152761344
author Helena Lucia Carneiro Santos
Karina M. Rebello
author_facet Helena Lucia Carneiro Santos
Karina M. Rebello
author_sort Helena Lucia Carneiro Santos
collection DOAJ
description Parasitic infections caused by protozoans that infect the mucosal surfaces are widely neglected worldwide. Collectively, Entamoeba histolytica, Giardia lamblia, Cryptosporidium spp. and Trichomonas vaginalis infect more than a billion people in the world, being a public health problem mainly in developing countries. However, the exact incidence and prevalence data depend on the population examined. These parasites ultimately cause pathologies that culminate in liver abscesses, malabsorption syndrome, vaginitis, and urethritis, respectively. Despite this, the antimicrobial agents currently used to treat these diseases are limited and often associated with adverse side effects and refractory cases due to the development of resistant parasites. The paucity of drug treatments, absence of vaccines and increasing problems of drug resistance are major concerns for their control and eradication. Herein, potential candidates are reviewed with the overall aim of determining the knowledge gaps and suggest future perspectives for research. This review focuses on this public health problem and focuses on the progress of drug repositioning as a potential strategy for the treatment of mucosal parasites.
first_indexed 2024-12-11T07:12:16Z
format Article
id doaj.art-f327dad493b54c648ca4bd700a00dfd8
institution Directory Open Access Journal
issn 2235-2988
language English
last_indexed 2024-12-11T07:12:16Z
publishDate 2022-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cellular and Infection Microbiology
spelling doaj.art-f327dad493b54c648ca4bd700a00dfd82022-12-22T01:16:20ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882022-04-011210.3389/fcimb.2022.860442860442An Overview of Mucosa-Associated Protozoa: Challenges in Chemotherapy and Future PerspectivesHelena Lucia Carneiro SantosKarina M. RebelloParasitic infections caused by protozoans that infect the mucosal surfaces are widely neglected worldwide. Collectively, Entamoeba histolytica, Giardia lamblia, Cryptosporidium spp. and Trichomonas vaginalis infect more than a billion people in the world, being a public health problem mainly in developing countries. However, the exact incidence and prevalence data depend on the population examined. These parasites ultimately cause pathologies that culminate in liver abscesses, malabsorption syndrome, vaginitis, and urethritis, respectively. Despite this, the antimicrobial agents currently used to treat these diseases are limited and often associated with adverse side effects and refractory cases due to the development of resistant parasites. The paucity of drug treatments, absence of vaccines and increasing problems of drug resistance are major concerns for their control and eradication. Herein, potential candidates are reviewed with the overall aim of determining the knowledge gaps and suggest future perspectives for research. This review focuses on this public health problem and focuses on the progress of drug repositioning as a potential strategy for the treatment of mucosal parasites.https://www.frontiersin.org/articles/10.3389/fcimb.2022.860442/fullEntamoeba histolyticaGiardia lambliaCryptosporidium spp.Trichomonas vaginalisreinfectiontreatment-refractory
spellingShingle Helena Lucia Carneiro Santos
Karina M. Rebello
An Overview of Mucosa-Associated Protozoa: Challenges in Chemotherapy and Future Perspectives
Frontiers in Cellular and Infection Microbiology
Entamoeba histolytica
Giardia lamblia
Cryptosporidium spp.
Trichomonas vaginalis
reinfection
treatment-refractory
title An Overview of Mucosa-Associated Protozoa: Challenges in Chemotherapy and Future Perspectives
title_full An Overview of Mucosa-Associated Protozoa: Challenges in Chemotherapy and Future Perspectives
title_fullStr An Overview of Mucosa-Associated Protozoa: Challenges in Chemotherapy and Future Perspectives
title_full_unstemmed An Overview of Mucosa-Associated Protozoa: Challenges in Chemotherapy and Future Perspectives
title_short An Overview of Mucosa-Associated Protozoa: Challenges in Chemotherapy and Future Perspectives
title_sort overview of mucosa associated protozoa challenges in chemotherapy and future perspectives
topic Entamoeba histolytica
Giardia lamblia
Cryptosporidium spp.
Trichomonas vaginalis
reinfection
treatment-refractory
url https://www.frontiersin.org/articles/10.3389/fcimb.2022.860442/full
work_keys_str_mv AT helenaluciacarneirosantos anoverviewofmucosaassociatedprotozoachallengesinchemotherapyandfutureperspectives
AT karinamrebello anoverviewofmucosaassociatedprotozoachallengesinchemotherapyandfutureperspectives
AT helenaluciacarneirosantos overviewofmucosaassociatedprotozoachallengesinchemotherapyandfutureperspectives
AT karinamrebello overviewofmucosaassociatedprotozoachallengesinchemotherapyandfutureperspectives